Europol calls India out for not policing drug counterfeiters; CPhI adds experts from Catalent, Piramal, IMS;

> A new report written in part by Europol takes India to task for not doing more to interrupt the manufacture of counterfeit meds that are ending up in Europe. Report

> CPhI has added Kurt Nielson of Catalent ($CTLT); Vivek Sharma of Piramal; and Alan Sheppard of IMS Health ($IMS) to its panel of experts for evaluating supply-chain trends. Release

> The European Federation of Pharmaceutical Industries and Associations says more flexibility in the EU's GMP guidance on qualification and validation would promote new technologies in the future. Report

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.